Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 9Gliosarcoma 6Brain Neoplasms 6Rectal Neoplasms 2Oligodendroglioma 2Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Neoplasms 2Astrocytoma 2Spinal Cord Neoplasms 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Optic Nerve Glioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1

Interventions

AZD 6244 11trametinib 4pirfenidone 3mirdametinib 2dabrafenib 2cabozantinib 2Imatinib Mesylate 2tipifarnib 1peginterferon alfa-2b 1nilotinib 1cediranib 1binimetinib 1Vinblastine 1Surveys and Questionnaires 1Sorafenib 1Pharmacokinetics 1Methotrexate 1Liquid Biopsy 1Gadolinium DTPA 1Fluorodeoxyglucose F18 1Everolimus 1Cryotherapy 1Control Groups 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibroma, Plexiform × cediranib × CNS × Clear all
NCT00326872 2017-08-18

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

National Cancer Institute (NCI)

Phase 2 Terminated
26 enrolled 8 charts
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡